Merrimack Pharmaceuticals is a biopharmaceutical company that receives payments related to its sale of: ONIVYDE® for the first-line treatment of metastatic adenocarcinoma of the pancreas, subject to certain conditions; ONIVYDE for the treatment of small-cell lung cancer after failure of first-line chemotherapy; and ONIVYDE for an additional indication unrelated to those described above; and payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Co. does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The MACK stock yearly return is shown above.
The yearly return on the MACK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MACK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|